Metastatic triple-negative breast cancer

Area of Science:

• Oncology
• Genetics

Background:

• Triple-negative breast cancer (TNBC) constitutes about 15% of all breast cancers.
• TNBC is associated with a poorer prognosis and higher rates of visceral metastasis compared to hormone receptor- or HER2-positive breast cancers.
• Despite initial chemotherapy sensitivity, metastatic TNBC often shows rapid relapse.

Purpose of the Study:

• To discuss the epidemiology, morphology, and molecular characteristics of TNBC.
• To highlight the clinical significance of TNBC.
• To review current and emerging therapeutic strategies for TNBC.

Main Methods:

• Literature review and synthesis of existing research on TNBC.
• Analysis of epidemiological data, morphological features, and molecular profiles.
• Examination of clinical trial data for targeted agents.

Main Results:

• TNBC shares molecular features with BRCA1-mutated and basal-like breast cancers.
• Specific TNBC markers, such as impaired DNA repair and increased proliferation markers, represent potential therapeutic targets.
• Investigational targeted agents include PARP inhibitors, EGFR inhibitors, and anti-angiogenic compounds.

Conclusions:

• TNBC presents unique challenges due to its aggressive nature and tendency for metastasis.
• Understanding TNBC's molecular landscape is crucial for developing effective clinical trials and novel therapies.
• Targeted therapies hold promise for improving outcomes in patients with TNBC.